Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Evaluation of novel cancer immunotherapies that combine the potency of chimeric antigen receptors and the intracellular targeting of T-cell receptors

FY 2016-17

Summary
Cancer is the leading cause of death in Canada and in many developed countries around the world. Recently, progress in the field of immunology has allowed for the development of "immunotherapies" against cancer. These allow doctors to use a patient's own immune system against their cancer. This can be done in three different approaches. One approach involves 'checkpoint' blockade drugs that decrease immune inhibition, leading to better-activated immune cells throughout the body and allowing immune cell-driven cancer cell killing. This strategy is most effective in tumours with a high number of mutations, such as melanoma, but due to the blanket nature of activation of the immune system this approach often leads to side effects. Another approach involves collecting tumour-associated immune cells surgically, treating them in the lab to strengthen them, and re-injecting them back into the patient. Finally, a third approach involves collecting a patient's immune cells and modifying them with an alternative targeting system, re-targeting them to the cancer. This re-targeting can be done with optimized natural receptors or with synthetic proteins - chimeric antigen receptors (CARs). In addition to re-targeting the cells, CARs also include co-stimulatory components, strengthening their anti-tumour response. This latter approach has so far been very successful in the clinic, and in a relapsed B cell acute lymphoblastic leukemia trial at MSKCC, it induced an 88% "overall complete response" rate. A limitation with CARs compared to naturally-occurring receptors is that they must target cell-surface targets and cannot, currently, target intracellular proteins. This makes designing tumour-specific therapies difficult. My project aims to evaluate three different ways of resolving this limitation by combining the intra-cellular scanning ability of naturally-occurring receptors with the higher efficacy of CARs, expanding the number of CAR-treatable cancers.
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Location
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365406
Name
Dobrin Anton
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Evaluation of novel cancer immunotherapies that combine the potency of chimeric antigen receptors and the intracellular targeting of T-cell receptors
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Cancer Immunotherapies; Cell Signalling; Chimeric Antigen Receptor Therapies; Lentiviral Vectors; Primary T Cell Culture; T-Cells; Transductions
Abstract
Cancer is the leading cause of death in Canada and in many developed countries around the world. Recently, progress in the field of immunology has allowed for the development of "immunotherapies" against cancer. These allow doctors to use a patient's own immune system against their cancer. This can be done in three different approaches. One approach involves 'checkpoint' blockade drugs that decrease immune inhibition, leading to better-activated immune cells throughout the body and allowing immune cell-driven cancer cell killing. This strategy is most effective in tumours with a high number of mutations, such as melanoma, but due to the blanket nature of activation of the immune system this approach often leads to side effects. Another approach involves collecting tumour-associated immune cells surgically, treating them in the lab to strengthen them, and re-injecting them back into the patient. Finally, a third approach involves collecting a patient's immune cells and modifying them with an alternative targeting system, re-targeting them to the cancer. This re-targeting can be done with optimized natural receptors or with synthetic proteins - chimeric antigen receptors (CARs). In addition to re-targeting the cells, CARs also include co-stimulatory components, strengthening their anti-tumour response. This latter approach has so far been very successful in the clinic, and in a relapsed B cell acute lymphoblastic leukemia trial at MSKCC, it induced an 88% "overall complete response" rate. A limitation with CARs compared to naturally-occurring receptors is that they must target cell-surface targets and cannot, currently, target intracellular proteins. This makes designing tumour-specific therapies difficult. My project aims to evaluate three different ways of resolving this limitation by combining the intra-cellular scanning ability of naturally-occurring receptors with the higher efficacy of CARs, expanding the number of CAR-treatable cancers.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Dobrin, Anton
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2016-17) | Canada Spends